DLBCL一线治疗后MRD:从代谢缓解到分子清除的连续谱
综述探讨弥漫大B细胞淋巴瘤一线治疗后FDG-PET代谢缓解与ctDNA-MRD检测的关系。PET与MRD捕捉部分重叠的治疗反应维度,PET阴性/MRD阳性提示隐匿残留病。MRD可优化PET后的预后分层,但标准化不足限制其常规决策应用。
要点
- PET代谢缓解不代表克隆清除,MRD可检测系统性克隆残留。
- PET阴性/MRD阳性可能反映隐匿残留病,需谨慎解读。
- MRD可优化完全代谢缓解患者的预后分层。
核心结论
- 代谢缓解反映优势肿瘤 compartment 控制,MRD检测识别持续存在的治疗抵抗克隆。
- 整合PET与MRD两个维度可改善治疗反应解读并指导治疗策略。
研究设计与样本
- 综述综合生物学、方法学与临床证据,探讨DLBCL一线治疗后PET与MRD的关系。
主要发现
- PET与MRD捕捉不同且仅部分重叠的治疗反应维度。
- PET阴性/MRD阳性可能由亚阈值代谢活性、弥漫低体积播散或微环境介导耐药驱动。
- MRD可在PET完全代谢缓解患者中进一步细化预后分层。
临床怎么用
- MRD目前不宜作为常规治疗决策触发因素,因技术变异、标准化有限且缺乏前瞻验证。
- 在自适应临床试验中可整合PET与MRD,将反应视为动态生物学过程。
局限性
- 技术变异、标准化有限及前瞻性验证不足限制MRD常规应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Response assessment in diffuse large B-cell lymphoma (DLBCL) has traditionally relied on anatomical and metabolic imaging, with fluorodeoxyglucose positron emission tomography (FDG-PET)-defined complete metabolic remission representing the principal end-point of first-line therapy. However, growing evidence indicates that metabolic control does not necessarily correspond to clonal eradication. Circulating tumour deoxyribonucleic acid (ctDNA)-based minimal residual disease (MRD) assessment offers a complementary perspective by detecting systemic clonal persistence rather than localized tumour burden. In this review, we synthesize biological, methodological and clinical evidence showing that PET and MRD capture distinct and only partially overlapping dimensions of treatment response. We discuss biological implications of PET-negative/MRD-positive status, which may represent occult residual disease driven by subthreshold metabolic activity, diffuse low-volume dissemination or microenvironment-mediated resistance. MRD may therefore refine prognostic stratification beyond PET, particularly among patients achieving complete metabolic responses. Nevertheless, technical variability, limited standardization and insufficient prospective validation currently limit its use as a routine therapeutic decision trigger. Emerging frameworks integrating PET and MRD, especially within adaptive clinical trials, conceptualize response as a dynamic biological process rather than a static classification. Overall, metabolic remission likely reflects control of dominant tumour compartments, whereas MRD detection identifies persisting therapy-resistant clones. Integrating both dimensions may improve interpretation and guide therapeutic strategies.
引用
- Caserta S, Martino EA, Vigna E, et al. Minimal residual disease in diffuse large B-cell lymphoma after first-line therapy: Defining the continuum from metabolic remission to molecular clearance. Br J Haematol. 2026. PMID: 42289802. doi:10.1111/bjh.70619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。